首页> 美国卫生研究院文献>other >The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold
【2h】

The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold

机译:核苷类似物抗病毒药的演变:化学家和非化学家的评论。第1部分:核苷支架的早期结构修饰

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This is the first of two invited articles reviewing the development of nucleoside-analogue antiviral drugs, written for a target audience of virologists and other non-chemists, as well as chemists who may not be familiar with the field. Rather than providing a simple chronological account, we have examined and attempted to explain the thought processes, advances in synthetic chemistry and lessons learned from antiviral testing that led to a few molecules being moved forward to eventual approval for human therapies, while others were discarded. The present paper focuses on early, relatively simplistic changes made to the nucleoside scaffold, beginning with modifications of the nucleoside sugars of Ara-C and other arabinose-derived nucleoside analogues in the 1960’s. A future paper will review more recent developments, focusing especially on more complex modifications, particularly those involving multiple changes to the nucleoside scaffold. We hope that these articles will help virologists and others outside the field of medicinal chemistry to understand why certain drugs were successfully developed, while the majority of candidate compounds encountered barriers due to low-yielding synthetic routes, toxicity or other problems that led to their abandonment.
机译:这是两篇受邀的文章中的第一篇,这些文章回顾了核苷类似物抗病毒药物的发展,专为病毒学家和其他非化学家以及可能不熟悉该领域的化学家的目标读者而写。我们没有提供简单的时间顺序说明,而是检查并试图解释其思想过程,合成化学的进展以及从抗病毒测试中学到的经验教训,这些经验使一些分子前进到最终批准用于人类疗法,而其他分子则被丢弃。本文着眼于对核苷支架的早期,相对简单的改变,首先是在1960年代对Ara-C和其他阿拉伯糖衍生的核苷类似物的核苷糖进行修饰。未来的论文将回顾更多的最新进展,尤其是更复杂的修饰,特别是涉及核苷支架多个改变的修饰。我们希望这些文章将帮助病毒学家和药物化学领域以外的其他人了解为什么成功开发了某些药物,而大多数候选化合物由于合成路线低,毒性或导致其被放弃的其他问题而遇到了障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号